HCPLive
49th Annual Meeting of the Infectious Diseases Society of America

IDSA 2011: Dr. Christian Loucq on Successful Initial Results of a Malaria Vaccine Trial [Podcast]

BOSTON, MA—In this interview at the annual conference of the Infectious Diseases Society of America, Christian Loucq, MD, director of the PATH Malaria Vaccine Initiative, discusses promising initial results of a Phase III trial of the experimental malaria vaccine RTS,S.

Most Popular

Recommended Reading

Generally, surgeons are gravitating toward shorter courses of antibiotics for surgical prophylaxis to reduce toxicity, selection of resistant organisms, Clostridium difficile infection, and cost.
Multiple sclerosis, especially in the relapsing form poses a variety of challenges for patient care. Keeping that in mind, the development of medications for the condition also take time to progress.
Ibuprofen and acetaminophen are among the well-known ingredients found in pain relievers, but an unusual addition that works just as well as existing medications may be making its way onto store shelves.
Developing drugs for conditions like multiple sclerosis takes a long time and a considerable amount of research. How the drugs are used, and changed is a delicate process undertaken between doctors and their patients over the course of the disease.
$vAR$